1. Home
  2. PLBY vs VYNE Comparison

PLBY vs VYNE Comparison

Compare PLBY & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBY

PLBY Group Inc.

HOLD

Current Price

$1.82

Market Cap

159.5M

ML Signal

HOLD

Logo VYNE Therapeutics Inc.

VYNE

VYNE Therapeutics Inc.

HOLD

Current Price

$0.65

Market Cap

21.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBY
VYNE
Founded
1953
2003
Country
United States
United States
Employees
N/A
10
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
159.5M
21.3M
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
PLBY
VYNE
Price
$1.82
$0.65
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$3.00
N/A
AVG Volume (30 Days)
809.7K
117.7K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
87.50
33.33
EPS
N/A
N/A
Revenue
$120,928,000.00
N/A
Revenue This Year
$9.17
N/A
Revenue Next Year
$7.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.13
N/A
52 Week Low
$0.93
$0.29
52 Week High
$2.75
$1.96

Technical Indicators

Market Signals
Indicator
PLBY
VYNE
Relative Strength Index (RSI) 57.94 61.77
Support Level $1.63 $0.56
Resistance Level $1.99 $0.75
Average True Range (ATR) 0.11 0.02
MACD 0.03 0.00
Stochastic Oscillator 68.67 96.66

Price Performance

Historical Comparison
PLBY
VYNE

About PLBY PLBY Group Inc.

Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

About VYNE VYNE Therapeutics Inc.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.

Share on Social Networks: